Brief: Adocia Files Patent On Hydrogen Scaffold For Type 1 Diabetes Treatment
Jan 11 (Reuters) - Adocia ADOC.PA :
* ANNOUNCED ON SATURDAY FILING PATENT ON A HYDROGEN SCAFFOLD
FOR
CELL THERAPY IN THE TREATMENT OF TYPE 1 DIABETES
* HYDROGEL SCAFFOLD CONTAINING PANCREATIC CELLS COULD
RESTORE
GLYCEMIC CONTROL WITHOUT REQUIRING INSULIN INJECTION AND
IMMUNOSUPPRESSANT DRUGS
Source text for Eikon: urn:newsml:reuters.com:*:nBw4yXfNqa
Further company coverage: ADOC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))
Recent news on Adocia SA
See all newsFrench biopharma firm Adocia H1 revenue drops on weaker feasibility study income
Brief: Adocia H1 Operating Income EUR -7.947 Million
Brief: Adocia Says Sanofi’S Exclusive Right For Partnership Agreement For Development Of M1Pram Has Expired
Brief: Adocia And Vester Finance Sign Shareholder Loan Agreement
Brief: Adocia Sees Challenges With GLP-1, Amylin & Other Metabolic Peptides